Myocardial Infarction (MI)HERO-AF-AMINCT07583784
Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI
A study testing DAT (DOAC+clopidogrel) and DOAC monotherapy in people with Myocardial Infarction (MI) and ST-Segment Elevation Myocardial Infarction(STEMI), run by Chonnam National University Hospital at 1 site in South Korea.
Trial summary
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI). Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Myocardial Infarction (MI), ST-Segment Elevation Myocardial Infarction(STEMI), NSTEMI - Non-ST-Segment Elevation Myocardial Infarction
- What is being tested?
- DAT (DOAC+clopidogrel) and DOAC monotherapy
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 860 participants
- Where
- 1 siteSouth Korea
- Study dates
- 26 Aug 2026to 31 Dec 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 19 years old
- Patients with AF and CHA2DS2-VA score ≥2.
- ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI)
- STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12
- NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12
- Symptoms of ischemia.
Show all 11Show fewer
- New or presumed new significant ST-T wave changes
- Development of pathological Q waves on electrocardiography.
- Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.
- Intracoronary thrombus detected on angiography.
- Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.
Who cannot join
- Patients contraindicated for use of DOACs or clopidogrel
- Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist
- Planned cardiac surgery within 1 year after randomization
- Patients with severe thrombocytopenia or coagulopathy
- Liver cirrhosis or severe hepatic dysfunction
- Advanced chronic kidney disease (creatinine clearance <15 ml/min/1.73 m2) or on dialysis
Show all 11Show fewer
- Prior history of intracranial hemorrhage
- Coexisting conditions related to high risk of life-threatening bleeding
- Pregnancy or breast feeding
- Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
- Unwillingness or inability to comply with the procedures described in this protocol.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Chonnam National University Hospital
Gwangju, Gwangju, 61469
Young Joon Hong, MD, PhD, 82-62-220-6246, hyj200@hanmail.net
Seung Hun Lee, MD, PhD
About this study
Official title: Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).
Read the detailed description
Advancements in device technologies for PCI and adjunct pharmacotherapy have recently shifted research focus toward balancing bleeding risk reduction with the management of ischemic events through novel antithrombotic strategies. These trends are particularly relevant for patients with atrial fibrillation (AF) who require lifelong oral anticoagulation to prevent embolic events. Traditionally, the combination of vitamin K antagonists (such as warfarin) with antiplatelet agents has been regarded as the standard approach to mitigate ischemic risk following PCI in patients with AF. However, previous studies have consistently demonstrated that dual antithrombotic therapy (DAT) utilizing direct oral anticoagulants (DOACs) results in reduced bleeding complications compared to triple antithrombotic therapy based on warfarin.
For long-term maintenance, DOAC monotherapy is recommended, as a Class I, after 6 to 12 months post-PCI for patients with stable coronary artery disease (CAD) and AF. Recent randomized clinical trials corroborate these recommendations. The AFIRE (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) study showed that rivaroxaban monotherapy was non-inferior to DAT in terms of both bleeding and ischemic outcomes. The EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) trial further extended this evidence, indicating that edoxaban monotherapy reduced the risk of net adverse clinical events (NACE)-a composite of death, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major or clinically relevant nonmajor bleeding-compared to DAT. Recently, the ADAPT AF-DES (Appropriate Duration of Antiplatelet and Thrombotic Strategy after 12 Months in Patients with Atrial Fibrillation Treated with Drug-Eluting Stents) trial demonstrated that DOAC monotherapy was non-inferior, and even superior, to combination therapy with a DOAC and clopidogrel regarding NACE reduction in patients with AF and stable CAD following PCI. However, these studies have primarily focused on patients with stable CAD who inherently have a lower ischemic risk. Despite limited evidence supporting DOAC monotherapy as a maintenance strategy for acute myocardial infarction (AMI) patients, recent guidelines have also recommended this approach after 1 year (Class I) or 6 months (Class IIB) following PCI in AMI setting. Furthermore, in real-world data, the DAT remained effective in reducing ischemic events without increasing the risk of bleeding compared with DOAC monotherapy. Additionally, DOAC monotherapy showed a lower risk of NACE at 3 years, but was not significantly effective at 1 year after PCI.
To address this critical evidence gap in clinical practice, we have developed the Heart-team for Evidence-based Revascularization: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and Acute Myocardial Infarction (HERO-AF-AMI). This study aims to evaluate the impact of DOAC monotherapy compared to DAT (DOAC plus clopidogrel) in patients with AF and AMI undergoing PCI.
- Conditions
- Myocardial Infarction (MI), ST-Segment Elevation Myocardial Infarction(STEMI), NSTEMI - Non-ST-Segment Elevation Myocardial Infarction, AF - Atrial Fibrillation
- Being tested
- DAT (DOAC+clopidogrel), DOAC monotherapy
- Keywords
- AF, Myocardial infarction, STEMI, NSTEMI, DOAC, NOAC, OAC alone
- Medical subject headings
- Myocardial Infarction, ST Elevation Myocardial Infarction, Atrial Fibrillation, Non-ST Elevated Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DAT (DOAC+clopidogrel)Drug
Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily.
DOAC monotherapyDrug
Patients allocated to the DOAC monotherapy group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily.
| Study group | Role | What they receive |
|---|---|---|
| DAT (DOAC+clopidogrel) group | Active comparator | Patients who were indicated lifelong oral anticoagulation for AF with a CHA2DS2-VA score equal to or greater than 2 points, and treated AMI with PCI are candidates. After 6 months of index procedure, the patients will be screened for inclusion and exclusion criteria, and eligible patients will be randomized into either the DOAC monotherapy group or the DAT group. Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily. Receives: Drug: DAT (DOAC+clopidogrel) |
| DOAC monotherapy group | Experimental | Patients who were indicated lifelong oral anticoagulation for AF with a CHA2DS2-VA score equal to or greater than 2 points, and treated AMI with PCI are candidates. After 6 months of index procedure, the patients will be screened for inclusion and exclusion criteria, and eligible patients will be randomized into either the DOAC monotherapy group or the DAT group. Patients allocated to the DOAC monotherapy group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily. Receives: Drug: DOAC monotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
NACE (net adverse clinical events)
a composite of death, non-fatal MI, stroke, systemic embolization, unplanned revascularization, stent thrombosis, major or clinically relevant non-major bleeding by ISTH
Measured: 1 year after the last patient enrollment
Secondary outcomes (15)
Rate of major bleeding by ISTH
major bleeding events by ISTH definition
Measured: 1 year after the last patient enrollment
Rate of MACCE (major adverse cardiac and cerebrovascular event)
a composite of cardiovascular death, non-fatal MI, ischemic stroke, systemic embolization, unplanned revascularization, and stent thrombosis
Measured: 1 year after the last patient enrollment
All-cause death
all-cause death
Measured: 1 year after the last patient enrollment
Cardiovascular death
cardiovascular death
Measured: 1 year after the last patient enrollment
Rate of non-fatal MI
non-fatal MI, defined by Fourth Universal definition of MI
Measured: 1 year after the last patient enrollment
Rate of ischemic stroke
ischemic stroke
Measured: 1 year after the last patient enrollment
Rate of systemic embolization
systemic embolization
Measured: 1 year after the last patient enrollment
Rate of unplanned revascularization
unplanned revascularization (clinically-driven)
Measured: 1 year after the last patient enrollment
Rate of definite stent thrombosis
definite stent thrombosis, defined by Academic Research Consortium (ARC) II consensus
Measured: 1 year after the last patient enrollment
Rate of cardiovascular death or non-fatal MI
a composite of cardiovascular death or non-fatal MI
Measured: 1 year after the last patient enrollment
Rate of all-cause death, non-fatal MI, stroke, systemic embolization, stent thrombosis, or ISTH major bleeding
a composite of all-cause death, non-fatal MI, stroke, systemic embolization, stent thrombosis, or ISTH major bleeding
Measured: 1 year after the last patient enrollment
Rate of major or clinically relevant non-major bleeding by ISTH
major or clinically relevant non-major bleeding by ISTH
Measured: 1 year after the last patient enrollment
Rate of fatal bleeding by ISTH
fatal bleeding by ISTH
Measured: 1 year after the last patient enrollment
Rate of clinically relevant non-major bleeding by ISTH
clinically relevant non-major bleeding by ISTH
Measured: 1 year after the last patient enrollment
Rate of any bleeding by ISTH
any bleeding by ISTH
Measured: 1 year after the last patient enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2026
- Study start26 Aug 2026
- Primary completion31 Dec 2031 (estimated)
- Study completion31 Dec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial Infarction (MI)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A prospective, multi-center, open label, randomized controlled, superiority trial to compare clinical outcomes between direct oral anticoagulants (DOAC) monotherapy versus DOAC and clopidogrel as maintenance strategies in AF and AMI patients after percutaneous coronary intervention (PCI)
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 860 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chonnam National University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Young Joon Hong, Chonnam National University Hospital
- Investigators
- Young Joon Hong, MD, PhD, Study chair, Chonnam National University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07583784
- Sponsor's protocol ID
- CNUH-AF-AMI
- Acronym
- HERO-AF-AMI
- Status last verified
- Aug 2026
- First submitted
- 7 May 2026
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: After publication of main paper, de-identified data will be shared upon reasonable requests after discussion by Executive Committee.
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction
- ClinicalTrials.gov ID
- NCT07583784
- Acronym / sponsor ID
- HERO-AF-AMI / CNUH-AF-AMI
- Conditions
- Myocardial Infarction (MI), ST-Segment Elevation Myocardial Infarction(STEMI), NSTEMI - Non-ST-Segment Elevation Myocardial Infarction, AF - Atrial Fibrillation
- Keywords
- AF, Myocardial infarction, STEMI, NSTEMI, DOAC, NOAC, OAC alone
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 860 participants (estimated)
- Lead sponsor
- Chonnam National University HospitalUniversity, hospital or other
- Study start
- 26 Aug 2026 (actual)
- Primary completion
- 31 Dec 2031 (estimated)
- Study completion
- 31 Dec 2032 (estimated)
- First posted
- 13 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).
Detailed description
Advancements in device technologies for PCI and adjunct pharmacotherapy have recently shifted research focus toward balancing bleeding risk reduction with the management of ischemic events through novel antithrombotic strategies. These trends are particularly relevant for patients with atrial fibrillation (AF) who require lifelong oral anticoagulation to prevent embolic events. Traditionally, the combination of vitamin K antagonists (such as warfarin) with antiplatelet agents has been regarded as the standard approach to mitigate ischemic risk following PCI in patients with AF. However, previous studies have consistently demonstrated that dual antithrombotic therapy (DAT) utilizing direct oral anticoagulants (DOACs) results in reduced bleeding complications compared to triple antithrombotic therapy based on warfarin.
For long-term maintenance, DOAC monotherapy is recommended, as a Class I, after 6 to 12 months post-PCI for patients with stable coronary artery disease (CAD) and AF. Recent randomized clinical trials corroborate these recommendations. The AFIRE (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) study showed that rivaroxaban monotherapy was non-inferior to DAT in terms of both bleeding and ischemic outcomes. The EPIC-CAD (Edoxaban versus Edoxaban with Antiplatelet Agent in Patients with Atrial Fibrillation and Chronic Stable Coronary Artery Disease) trial further extended this evidence, indicating that edoxaban monotherapy reduced the risk of net adverse clinical events (NACE)-a composite of death, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, and major or clinically relevant nonmajor bleeding-compared to DAT. Recently, the ADAPT AF-DES (Appropriate Duration of Antiplatelet and Thrombotic Strategy after 12 Months in Patients with Atrial Fibrillation Treated with Drug-Eluting Stents) trial demonstrated that DOAC monotherapy was non-inferior, and even superior, to combination therapy with a DOAC and clopidogrel regarding NACE reduction in patients with AF and stable CAD following PCI. However, these studies have primarily focused on patients with stable CAD who inherently have a lower ischemic risk. Despite limited evidence supporting DOAC monotherapy as a maintenance strategy for acute myocardial infarction (AMI) patients, recent guidelines have also recommended this approach after 1 year (Class I) or 6 months (Class IIB) following PCI in AMI setting. Furthermore, in real-world data, the DAT remained effective in reducing ischemic events without increasing the risk of bleeding compared with DOAC monotherapy. Additionally, DOAC monotherapy showed a lower risk of NACE at 3 years, but was not significantly effective at 1 year after PCI.
To address this critical evidence gap in clinical practice, we have developed the Heart-team for Evidence-based Revascularization: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation and Acute Myocardial Infarction (HERO-AF-AMI). This study aims to evaluate the impact of DOAC monotherapy compared to DAT (DOAC plus clopidogrel) in patients with AF and AMI undergoing PCI.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- A prospective, multi-center, open label, randomized controlled, superiority trial to compare clinical outcomes between direct oral anticoagulants (DOAC) monotherapy versus DOAC and clopidogrel as maintenance strategies in AF and AMI patients after percutaneous coronary intervention (PCI)
| Arm | Type | Receives |
|---|---|---|
| DAT (DOAC+clopidogrel) group | Active comparator | Drug: DAT (DOAC+clopidogrel)Patients who were indicated lifelong oral anticoagulation for AF with a CHA2DS2-VA score equal to or greater than 2 points, and treated AMI with PCI are candidates. After 6 months of index procedure, the patients will be screened for inclusion and exclusion criteria, and eligible patients will be randomized into either the DOAC monotherapy group or the DAT group. Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily. |
| DOAC monotherapy group | Experimental | Drug: DOAC monotherapyPatients who were indicated lifelong oral anticoagulation for AF with a CHA2DS2-VA score equal to or greater than 2 points, and treated AMI with PCI are candidates. After 6 months of index procedure, the patients will be screened for inclusion and exclusion criteria, and eligible patients will be randomized into either the DOAC monotherapy group or the DAT group. Patients allocated to the DOAC monotherapy group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily. |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Patients aged 19 years old
- Patients with AF and CHA2DS2-VA score ≥2.
- ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI)
- Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.
Key exclusion criteria (11 listed)
- Patients contraindicated for use of DOACs or clopidogrel
- Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist
- Planned cardiac surgery within 1 year after randomization
- Patients with severe thrombocytopenia or coagulopathy
- Liver cirrhosis or severe hepatic dysfunction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DAT (DOAC+clopidogrel)Patients allocated to the DAT group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 15 mg once daily with clopidogrel 75 mg once daily. | Drug | DAT (DOAC+clopidogrel) group |
| DOAC monotherapyPatients allocated to the DOAC monotherapy group receive either apixaban 5 mg twice daily, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily. | Drug | DOAC monotherapy group |
Primary outcome
NACE (net adverse clinical events)
Time frame: 1 year after the last patient enrollment
a composite of death, non-fatal MI, stroke, systemic embolization, unplanned revascularization, stent thrombosis, major or clinically relevant non-major bleeding by ISTH
15 secondary outcomes
Rate of major bleeding by ISTH
Time frame: 1 year after the last patient enrollment
Rate of MACCE (major adverse cardiac and cerebrovascular event)
Time frame: 1 year after the last patient enrollment
All-cause death
Time frame: 1 year after the last patient enrollment
Cardiovascular death
Time frame: 1 year after the last patient enrollment
Rate of non-fatal MI
Time frame: 1 year after the last patient enrollment
Rate of ischemic stroke
Time frame: 1 year after the last patient enrollment
Rate of systemic embolization
Time frame: 1 year after the last patient enrollment
Rate of unplanned revascularization
Time frame: 1 year after the last patient enrollment
Rate of definite stent thrombosis
Time frame: 1 year after the last patient enrollment
Rate of cardiovascular death or non-fatal MI
Time frame: 1 year after the last patient enrollment
Rate of all-cause death, non-fatal MI, stroke, systemic embolization, stent thrombosis, or ISTH major bleeding
Time frame: 1 year after the last patient enrollment
Rate of major or clinically relevant non-major bleeding by ISTH
Time frame: 1 year after the last patient enrollment
Rate of fatal bleeding by ISTH
Time frame: 1 year after the last patient enrollment
Rate of clinically relevant non-major bleeding by ISTH
Time frame: 1 year after the last patient enrollment
Rate of any bleeding by ISTH
Time frame: 1 year after the last patient enrollment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
- Individual participant dataSharing planned: Yes. After publication of main paper, de-identified data will be shared upon reasonable requests after discussion by Executive Committee.
Related trials for Myocardial Infarction (MI)
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
RecruitingObservational study
Breisgau PHENO-HEART MI
Myocardial Infarction, STEMI
Not yet recruiting
Pilot Study to Determine the Optimal Protocol for Preoperative Transcutaneous Vagal Neurostimulation
Atrial Fibrillation (AF), Cerebral Vascular Accident (CVA)
Recruiting
Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
Myocardial Infarction (MI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Young Joon Hong, MD, PhD study chair
Chonnam National University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing DAT (DOAC+clopidogrel) and DOAC monotherapy in people with Myocardial Infarction (MI) and ST-Segment Elevation Myocardial Infarction(STEMI), run by Chonnam National University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Seung Hun Lee, MD, PhD (82-2-220-6246, lsh8602@naver.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
NACE (net adverse clinical events) (time frame: 1 year after the last patient enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.